L
1.74
0.00 (0.00%)
| Previous Close | 1.74 |
| Open | 1.74 |
| Avg. Volume (3M) | 347,913 |
| Market Cap | 45,771,216 |
| Price / Sales | 9.38 |
| Price / Book | 3.61 |
| 52 Weeks Range | |
| Earnings Date | 18 Aug 2025 - 22 Aug 2025 |
| Operating Margin (TTM) | -628.16% |
| Diluted EPS (TTM) | -1.05 |
| Quarterly Revenue Growth (YOY) | 1,313.60% |
| Total Debt/Equity (MRQ) | 1.21% |
| Current Ratio (MRQ) | 6.73 |
| Operating Cash Flow (TTM) | -30.35 M |
| Levered Free Cash Flow (TTM) | -15.16 M |
| Return on Assets (TTM) | -23.02% |
| Return on Equity (TTM) | -73.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | LAVA Therapeutics N.V. | Bearish | Bearish |
AIStockmoo Score
-0.6
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.63 |
|
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 32.69% |
| % Held by Institutions | 36.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jbf Capital, Inc. | 30 Sep 2025 | 23,911 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |